Table 3.
Association of EpCAM overexpression with the clinicopathological characteristics from The Cancer Genome Atlas (TCGA)
| Factors | Total (N) | OR with 95% CI | P |
|---|---|---|---|
| Age (≥ 61 vs. < 61) | 495 | 0.72 (0.5–1.02) | 0.065 |
| T stage (T3–4 vs. T1–2) | 488 | 0.95 (0.66–1.37) | 0.78 |
| Lymph node metastasis (Positive vs. Negative) | 422 | 1.04 (0.63–1.69) | 0.889 |
| Number of lymph node (> 10 vs. ≤ 10) | 420 | 1.18 (0.81–1.74) | 0.39 |
| Biochemical recurrence (Yes vs. No) | 427 | 0.79 (0.45–1.38) | 0.408 |
| Gleason score (≥ 7 vs. ≤ 6) | 483 | 1.19 (0.66–2.14) | 0.561 |
| PSA value ( ≥ 10 vs. < 10) | 438 | 1.75 (0.62–4.89) | 0.288 |
N number of the study population, PSA prostate-specific antigen, OR odds ratio, 95% CI 95% confidence interval